5 completed, 3 terminated, 2 recruiting. 10 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 3, Recruiting 2 |
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy NIO752, Placebo - Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | Phase 3 | Recruiting | Novartis Pharmaceuticals | 300 | 2026-06-03 | 2026-10-15 |
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
| PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620 [18F]-PI-2620 - Frontotemporal Lobar Degeneration, Alzheimer Disease | Phase 3 | Recruiting | University of Pennsylvania | 72 | 2022-09-19 | 2026-09-21 |
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001 - Frontotemporal Dementia | Phase 3 | Terminated | Alector Inc. | 119 | 2020-07-23 | 2026-09-21 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD) LMTM - Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia | Phase 3 | Terminated | TauRx Therapeutics Ltd | 913 | 2014-08-01 | 2023-05-24 |
| Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD) TRx0237, Placebo - Behavioral Variant Frontotemporal Dementia (bvFTD) | Phase 3 | Completed | TauRx Therapeutics Ltd | 220 | 2013-05-01 | 2018-03-14 |
| Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia memantine hydrochloride - Frontotemporal Dementia | Phase 3 | Completed | Tiffany Chow, MD | 17 | 2007-10-01 | 2012-06-04 |
| Effects of Doxycycline and Rifampicin on Biomarkers of Alzheimer's Disease in the Cerebrospinal Fluid doxycycline, rifampicin, Placebo matched to doxycycline - Alzheimer's Disease | Phase 3 | Completed | Hamilton Health Sciences Corporation | 100 | 2007-02-01 | 2018-03-19 |
| COGNIShunt® System for Alzheimer's Disease The COGNIShunt® System - Alzheimer Disease | Phase 3 | Completed | Eunoe | 250 | 2001-01-01 | 2006-09-12 |
Frontotemporal Dementia (6) · Alzheimer Disease (5) · Pick Disease of the Brain (4) · Dementia (3) · Cognitive Dysfunction (2) · Neurodegenerative Diseases (2) · Amyotrophic Lateral Sclerosis (1) · Brain Diseases (1) · Chronobiology Disorders (1) · Dementia, Vascular (1) · Disorders of Excessive Somnolence (1) · Memory Disorders (1) · Neurocognitive Disorders (1) · Plaque, Amyloid (1)
Central Nervous System Diseases (10) · Mental Disorders (10) · Nervous System Diseases (10) · Brain Diseases (9) · Neurocognitive Disorders (9) · Neurodegenerative Diseases (8) · Dementia (7) · Metabolic Diseases (7) · Nutritional and Metabolic Diseases (7) · Proteostasis Deficiencies (7) · TDP-43 Proteinopathies (7) · Tauopathies (6) · Frontotemporal Dementia (3) · Pathological Conditions, Signs and Symptoms (3)
((18)F)PI-2620 (1) · Doxycycline (1) · Memantine (1) · Rifampin (1) · hydromethylthionine (1)
Alector Inc. (2) · TauRx Therapeutics Ltd (2) · University of Pennsylvania (2) · Eunoe (1) · Hamilton Health Sciences Corporation (1) · Novartis Pharmaceuticals (1) · Tiffany Chow, MD (1)
United States (7) · Canada (6) · Germany (5) · Netherlands (5) · United Kingdom (5) · Australia (4) · Belgium (4) · France (4) · Italy (4) · Spain (4) · Croatia (2) · Portugal (2) · Romania (2) · Singapore (2) · South Korea (2)
Alwin Cunje, MD, PhD (1) · Brandon M Kucher, PhD (1) · David D Cowan, MD, FRCPC (1) · Dawn McGuire, MD, Chief Scientific Officer (1) · Jeffrey S Phillips (1) · Nancy A. Hodgson (1) · Tiffany W Chow, MD (1) · Tim I Standish, MA (1) · Tricia KW Woo, MD, FRCPC (1) · William Molloy, MB, FRCPC (1)
PMID 21792308, PMID 22674572, PMID 24819148, PMID 33853394, PMID 34344312
2023 (1), R01NR015226 (1)